Birmingham, AL, August 1st 2019 – Vulcan Biosciences, Inc. a biotechnology company focused on finding more effective treatments for patients with multiple sclerosis, announced today that it has secured an undisclosed amount in a seed funding round from Birmingham area angel investors. The funds raised will be utilized in a drug discovery program whose sole purpose is to identify better treatments for patients with multiple sclerosis, the most common autoimmune disease of the central nervous system.